Top Markets
Coin of the day
Apexigen, Inc. Apexigen, Inc.

Apexigen, Inc.

APGN
株式のランク #36265
Apexigen Inc., established in 2010 and based in San Carlos, California, is a... Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.
株価
$0.385
最終同期: 2023-09-01
時価総額
$2.86M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Apexigen, Inc. (APGN)

カテゴリー

Apexigen, Inc.(APGN)の発行済株式数
August 2026 時点の発行済株式数 0
Apexigen, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。August 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Apexigen, Inc.(APGN)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M -
US
62.19M -
NL
- -
CH
- -
KR
0.00 -
BE